The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Επικοινωνία Submitted by Στέργιος Πολύζος on Σάβ, 09/12/2020 - 22:22
